4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6

  • J Med Chem. 2010 Nov 25;53(22):7938-57. doi: 10.1021/jm100571n.
Young Shin Cho  1 ,  Maria Borland ,  Christopher Brain ,  Christine H-T Chen ,  Hong Cheng ,  Rajiv Chopra ,  Kristy Chung ,  James Groarke ,  Guo He ,  Ying Hou ,  Sunkyu Kim ,  Steven Kovats ,  Yipin Lu ,  Marc O'Reilly ,  Junqing Shen ,  Troy Smith ,  Gary Trakshel ,  Markus Vögtle ,  Mei Xu ,  Ming Xu ,  Moo Je Sung
Affiliations
  • 1. Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA. youngshin.cho@novartis
PMID: 21038853 DOI: 10.1021/jm100571n
Abstract

Identification and structure-guided optimization of a series of 4-(pyrazol-4-yl)-pyrimidines as selective CDK4/6 inhibitors is reported herein. Several potency and selectivity determinants were established based on the X-ray crystallographic analysis of representative compounds bound to monomeric CDK6. Significant selectivity for CDK4/6 over CDK1 and CDK2 was demonstrated with several compounds in both enzymatic and cellular assays.

Products